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Abstract
Background: While it is believed that total arterial grafting (TAG) for coronary artery bypass
grafting (CABG) confers improved long-term outcomes when compared to conventional grafting
with left internal mammary artery and saphenous vein grafts (LIMA+SVG), to date, this has not
become the standard of care. In this study, we assessed the impact of TAG on medium-term
outcomes after CABG.
Methods:  Peri-operative data was prospectively collected on consecutive first-time, isolated
CABG patients between 1995 and 2005. Patients were divided into two groups based on grafting
strategy: TAG (all arterial grafts no saphenous veins) or LIMA+SVG. Patients who had an emergent
status or underwent fewer than two distal bypasses were excluded. Medium term univariate and
risk-adjusted comparisons between TAG and LIMA+SVG cases were performed.
Results: A total of 4696 CABG patients were included with 1019 patients undergoing TAG (22%).
Unadjusted in-hospital mortality was 1.5% for TAG patients compared to 2.0% for LIMA+SVG (p
= 0.31). The mean follow-up was 4.8 ± 2.0 years for TAG patients compared to 6.1 ± 3.0 years for
LIMA+SVG patients (p < 0.0001). At follow-up total mortality (8% vs 19%; p < 0.0001), and the
incidence of readmission to hospital for cardiac reasons (29% vs 38%; p < 0.0001) were significantly
lower in TAG compared to LIMA+SVG patients. However, after adjusting for clinical covariates,
TAG did not emerge as a significant independent predictor of long-term mortality (HR 0.92; CI
0.71–1.18), readmission to hospital (HR 1.02; CI 0.89–1.18) or the composite outcome of mortality
and readmission (HR 1.00; CI 0.88–1.15). Risk adjusted survival was better than 88% in both TAG
and LIMA-SVG patients at 5 years follow-up.
Conclusion: Patients undergoing TAG appear to experience lower rates of medium-term all-
cause mortality and readmission to hospital for any cardiac cause when compared to patients
undergoing LIMA+SVG. However, after adjusting for clinical variables, this difference no longer
persists suggesting that at median follow-up there are no mortality or morbidity benefit based on
the choice of conduit.
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Introduction
Since its introduction nearly four decades ago, coronary
artery bypass grafting (CABG) has established itself as an
important therapeutic intervention for patients with
symptomatic coronary artery disease. In addition to pro-
viding symptom relief, CABG has been shown to provide
significant survival benefits with acceptable post-opera-
tive morbidity and mortality. Even as the average level of
co-morbid illness and surgical acuity continues to rise
among patients referred for CABG, risk-adjusted rates of
in-hospital mortality following CABG have steadily
declined, owing in large part to the ongoing advance-
ments in the peri-operative management of patients
undergoing CABG and improved surgical technique [1,2].
While short-term results following CABG are generally
undisputed, long-term results have been more uncertain.
During the early to mid 1980's, reports emerged in the lit-
erature describing the considerably diminished long-term
patency rates of saphenous vein grafts (SVG), eventually
leading to SVG occlusion which would result in the inev-
itable recurrence of symptoms, the need for readmission
to hospitalization and coronary re-intervention and pos-
sibly even death [3,4]. However, around the same time,
publications exalting the superior long-term patency rates
of the left internal mammary artery (LIMA) graft and the
improved long-term survival associated with grafting of
the LIMA to the left anterior descending (LAD) artery sur-
faced, re-establishing confidence in the long-term benefits
of CABG [3-5]. Consequently, LIMA used in combination
with SVG (LIMA+SVG) became the standard or conven-
tional strategy employed during CABG procedures.
With the success of LIMA grafts, it seemed intuitive that
using other arterial conduits such as the right internal
mammary artery (RIMA), the radial artery (RA) and/or the
gastroepiploic artery (GEPA) in conjunction with LIMA
grafts would further improve long-term outcomes. In fact,
studies showed that LIMA + RIMA was associated with
improved long-term survival and diminished rates of
angina recurrence and late MI and that RA grafts were
associated with improved short-term and long-term pat-
ency rates [6-10]. These results generated considerable
interest in the complete elimination of SVG altogether
and the institution of total arterial grafting (TAG) for the
purposes of improving long-term results following CABG
[11-20].
To date, studies looking at the efficacy of TAG as com-
pared to traditional strategies using LIMA+SVG have
focused primarily on short-term outcomes following sur-
gery and have provided mixed results. Royse et al demon-
strated that TAG was associated with reduced in-hospital
mortality, while Muneretto et al, in a series of randomized
controlled trials, showed that while rates of in-hospital
mortality were not different between the two groups, inci-
dence of angina recurrence and graft occlusion at approx-
imately one year was significantly lower in the group
receiving TAG [16-19]. Legare et al, using propensity score
analysis, compared patients undergoing TAG with com-
posite arterial grafts to a matched group of patients receiv-
ing LIMA+SVG and found that TAG was independently
associated with higher rates of post-operative morbidity
even though a mortality difference was not demonstrable
[20]. More recently, Guru et al reported improved risk-
adjusted survival and greater freedom from cardiac mor-
bidity in patients with multiple arterial grafts (12% of
patients with multiple arterial grafts) as compared to hose
with single arterial grafts [21].
The objective of this study is to determine the effect of
TAG on medium-term outcomes following CABG. This
study addresses some of the limitations of previous stud-
ies in terms of sample size, duration of follow-up and con-
founding introduced by the inclusion of patients with
multiple but not total arterial grafts.
Materials and methods
Patients
All patients who underwent isolated, on-pump CABG at
the Queen Elizabeth II (QEII) Health Sciences Center
from 1995 until 2003, in Halifax, Canada, were identified
using the Maritime Heart Center (MHC) database. From
this group, only those patients who underwent CABG
using TAG or LIMA+SVG were included for consideration
in the final analysis. Patients were excluded from the final
analysis if they underwent single-vessel bypass surgery or
if they required an emergent or emergent salvage proce-
dure. In both groups only patients with a LIMA to the left
anterior descending artery were included.
Operative Technique
All interventions were performed via a midline sternot-
omy, and cardiopulmonary bypass was instituted in a
standardized manner for all cases. Briefly, body tempera-
ture during the procedure was allowed to drift to 32°C.
Intermittent cold cardioplegia solution was delivered
antegrade via the aortic root unless otherwise indicated.
Arterial conduits were harvested with minimal trauma
(LIMA and RIMA were not skeletonized) and were treated
with either a papaverine solution or a nitroglycerine/cal-
cium channel blocker (verapamil) solution prior to their
use.
TAG was defined as the use of any arterial conduit (LIMA,
RIMA, RA or GEPA), either alone or in combination, with-
out concomitant use of SVG. The choice of conduit and
the manner in which the grafts were constructed, includ-
ing whether or not grafts were constructed in a composite
T- or Y- fashion, proximal aorto-coronary anastomosesJournal of Cardiothoracic Surgery 2007, 2:44 http://www.cardiothoracicsurgery.org/content/2/1/44
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were performed or sequential anastomoses were used, was
based entirely on surgeon preference rather than on any
fixed criteria such as territory to graft or degree of target
vessel stenosis. LIMA+SVG, on the other hand, was
defined as any case in which the LIMA was used for the
purposes of a single bypass to the left anterior coronary
artery (LAD) and the remaining bypasses were carried out
using SVG. In these cases, SVG were constructed as either
a series of sequential anastomoses or as single bypasses
and were anastomosed proximally to the aorta.
Post-operative Management
All patients received intravenous nitroglycerine infusions
for the first 24 hours upon return from the operating
room unless hypotensive (systolic blood pressure < 90
mm Hg). Oral nifedipine (Adalat 10 mg by mouth 4 times
a day or Adalat extended release (XL) 20 to 30 mg by
mouth daily; Bayer Inc., Toronto, Ontario, Canada) was
prescribed for all patients receiving a radial artery begin-
ning on day 1 post-operatively for a period of 3 to 6
months. Other routine post-operative medications
included daily aspirin as well as resumption of cholesterol
lowering agents, β-blockers and angiotensin converting
enzyme inhibitors as appropriate.
Data Sources
The MHC database captures detailed information on a
wide range of pre-operative, intra-operative, and in-hospi-
tal post-operative variables including post-operative com-
plications and in-hospital mortality for all patients
undergoing cardiac surgery at the QEII Health Sciences
Center in Nova Scotia, Canada. In order to gather infor-
mation regarding long-term outcomes, the MHC database
was linked to the Canadian Institute for Health Informa-
tion (CIHI) Discharge Abstract Database and the Nova
Scotia Vital Statistics database. The CIHI Discharge
Abstract Database is a national database that contains
extensive data for each inpatient and outpatient hospital
visit in Nova Scotia and enables us to track all readmis-
sions to hospital. The Nova Scotia Vital Statistics database
collects information on all births and deaths occurring
within the province of Nova Scotia.
Variable Selection
Pre-operative variables of interest included age (age ≥ 70
vs. age < 70), gender, body mass index or BMI (BMI > 25
kg/m2 vs. BMI = 25 kg/m2), smoking history, diabetes,
hypercholesterolemia, renal insufficiency (pre-operative
serum creatinine of ≥ 176 µmol/L), hypertension, periph-
eral and/or cerebrovascular disease, left ventricular ejec-
tion fraction or EF (EF < 40% vs. EF ≥ 40%), recent
myocardial infarction (MI) defined as the occurrence of
an MI in the 21 days prior to surgery, pre-operative ino-
tropes/intra-aortic balloon pump (IABP) use, New York
Heart Association (NYHA) functional classification
(NYHA class IV vs. NYHA classes I – III), urgency status
(operation performed within 24 hours from the time of
referral vs. operation performed at a time interval of
greater than 24 hours from the time of referral), prior per-
cutaneous coronary intervention (PCI) and number of
diseased vessels (triple-vessel or left main disease vs. sin-
gle- or double-vessel disease). As mentioned earlier,
patients undergoing emergent or emergent salvage proce-
dures were excluded. Intra-operative variables of interest
included number of distal anastomoses, cross clamp time
and total bypass time. The medium-term outcomes of
interest included all-cause mortality following discharge
from hospital, readmission to hospital for any cardiac
cause as defined by the following codes from the ninth
revision of the International Classification of Disease,
Clinical Modification (ICD-9-CM) (20): 410 (acute myo-
cardial infarction), 411 (unstable angina), 412 (old myo-
cardial infarction), 413 (angina pectoris), 414 (other
forms of chronic IHD), 426 (conduction disorders), 427
(cardiac dysrhythmias), 428 (heart failure), 429 (ill-
defined descriptions and complications of heart disease),
coronary re-intervention (PCI or CABG) and a composite
outcome defined as all-cause mortality following dis-
charge from hospital or readmission to hospital for any
cardiac cause.
Statistical Analysis
Univariate comparisons between cases performed using
TAG and cases performed using LIMA+SVG were carried
out based on pre-, intra-, and post-operative variables
including rates of in-hospital mortality and long-term
adverse events using Chi-square tests for dichotomous
variables and two-tailed t-tests for continuous variables.
Unadjusted rates of the long-term composite outcome
were then compared between TAG and LIMA+SVG cases
using Kaplan Meier survival plots and the log-rank test. A
fully-adjusted Cox proportional hazard model was cre-
ated to determine the effect of TAG on the long-term out-
come of interest after adjusting for differences between
patients in clinical presentation. Pre-operative variables
regardless of whether or not they differed between TAG
and LIMA+SVG were included in the model building
process, and a non-parsimonious model was created that
retained all variables. The following variables were used in
the model: age groups, COPD, gender, diabetes, preop
renal insufficiency, cerebrovascular disease, peripheral
vascular disease, EF groups, congestive heart failure,
urgency status, number of diseased vessels, group assign-
ment (TAG vs LIMA+SVG) and propensity analysis score
(p score). A propensity score was calculated for each
patient using the predicted probability of being in the
TAG group. A multinomial logistic regression model was
used to predict the probability of TAG group assignment
(p score) after adjusting for all relevant preoperative
patient characteristics including era (1995–2000 vs 2000–Journal of Cardiothoracic Surgery 2007, 2:44 http://www.cardiothoracicsurgery.org/content/2/1/44
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2005). Statistical significance was set at p < 0.05. All sta-
tistical analyses were performed using the SAS software
package version 8.2 (SAS, Cary, North Carolina).
Results
A total of 4696 patients underwent first-time, isolated, on-
pump, non-emergent CABG with greater than a single
bypass between March 1, 1995 and March 31, 2005 using
either TAG (n = 1019) or LIMA+SVG (n = 3677). Patient
characteristics of the two groups are shown in Table 1.
When compared to patients undergoing LIMA+SVG,
patients receiving TAG were younger, more likely to be
male and less likely to have hypercholesterolemia, renal
failure, peripheral vascular disease and triple vessel or left
main disease. TAG patients also had better heart function
and were operated more on an elective basis.
The proportion of TAG was 22% of all CABG patients dur-
ing the study period. The conduits used for TAG patients
were: the left internal mammary artery (LIMA; 100%),
right internal mammary artery (RIMA; 39%), and radial
artery (62%). Overall there were fewer distal anatomoses
performed in TAG patients (3.1 ± 0.9 grafts) compared to
LIMA+SVG patients (3.2 ± 0.8 grafts; p < 0.001) (Table 1).
Unadjusted in-hospital mortality was 1.5% for TAG
patients compared to 2.0% for LIMA+SVG (p = 0.31).
Similarly unadjusted rates of in-hospital permanent
stroke or post-operative myocardial infarction did not dif-
fer significantly between the two groups (Table 2). The
unadjusted median length of hospitalization was 6 days
(IQR 5–7) for TAG group compared to 7 days (IQR 5–8)
for the LIMA+SVG group (p < 0.0001).
The median follow-up was 4.5 ± 2.0 years for TAG patients
compared to 6.2 ± 3.0 years for LIMA+SVG patients (p <
0.0001). Over the entire follow-up period, 86 patients
(8.4%) had died in the TAG group compared to 683
patients (18.6%) in the LIMA+SVG group (p < 0.0001)
(Table 2). After adjusting for clinical covariates, TAG did
not emerge as a significant independent predictor of long-
term mortality (HR 0.92; CI 0.71–1.18). Risk adjusted
survival was better than 88% in both TAG and LIMA-SVG
patients at 5 years follow-up (Figure 1).
Following discharge 29% of TAG patients were readmitted
to hospital for any cardiac reasons as compared to 38% of
LIMA+SVG patients (p < 0.0001). This included 58
(5.7%) TAG patients vs 153 (4.3%) LIMA+SVG patients
who were readmitted for repeat revascularization in the
form of PCI or CABG surgery (p = 0.04). The incidence of
repeat CABG was 5 (0.5%) TAG patients compared to 31
(0.8%) LIMA+SVG patients (p = 0.25). After adjusting for
clinical covariates, TAG did not emerge as a significant
independent predictor of readmission to hospital (HR
1.02; CI 0.88–1.18). Risk adjusted freedom from readmis-
sion to hospital, for any cardiac reason curves are illus-
trated in figure 2.
Table 1: Comparing pre- and intra-operative characteristics among patients undergoing CABG with TAG and with LIMA+SVG.
Variable TAG n (%) LIMA+SVG n (%) p-value
Age 60.2 ± 9.7 yrs 65.8 ± 9.8 yrs < 0.0001
Female sex 205 (20) 995 (27) < 0.0001
Smoking history 732 (72) 2565 (70) 0.20
Diabetes 347 (34) 1360 (37) 0.08
Hypercholesterolemia 902 (88) 2703 (74) < 0.0001
Pre-op renal failure 16 (2) 218 (6) < 0.0001
Hypertension 629 (62) 2368 (64) 0.12
Peripheral vascular disease 138 (14) 623 (17) 0.009
Cerebrovascular disease 84 (8) 525 (14) < 0.0001
Ejection fraction > 50 831 (82) 2711 (76) < 0.0001
30–50 168 (16) 706 (19)
< 30 20 (2) 197 (5)
Recent MI < 7d 36 (4) 208 (6) 0.007
Pre-op IABP 27 (3) 182 (5) 0.002
CHF 77 (8) 539 (15) < 0.0001
COPD 120 (12) 429 (14) 0.033
Urgent (< 24 hours) Elective 615 (60) 1811 (49) < 0.0001
IHU 331 (32) 1421 (39)
Urgent 73 (7) 445 (12)
Prior PCI 126 (12) 366 (10) 0.026
Left-main/triple-vessel disease 789 (77) 3145 (86) < 0.0001
Number of bypasses 3.1+0.9 grafts 3.2+0.8 grafts < 0.0001
BMI, Body mass index; CHF, history of congestive heart failure; COPD, chronic obstructive lung disease; MI, myocardial infarction; IABP, intra-
aortic balloon pump; IHU, in-hospital urgent i.e. waiting for surgery in-hospital longer than 24 hrs; PCI, percutaneous coronary intervention.Journal of Cardiothoracic Surgery 2007, 2:44 http://www.cardiothoracicsurgery.org/content/2/1/44
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We then used the composite outcome of death or
readmission to hospital for cardiac reason to compare
TAG and LIMA+SVG patients. Utilizing unadjusted data
we were able to show that TAG offers a significantly higher
freedom from the composite adverse outcome when com-
pared to LIMA+SVG patients (Figure 3). However, after
adjusting for clinical covariates, TAG was no longer asso-
ciated with improved freedom from the composite out-
come of all-cause mortality or readmission to hospital for
any cardiac cause over time (HR 1.00, 95% CI 0.88 – 1.15)
(Figure 3).
The following variables were found to be independent
predictors of the composite outcome (death and/or
readmission to hospital for any cardiac cause): increased
age (> 70), COPD, female gender, diabetes, pre-operative
renal insufficiency, peripheral vascular disease, low ejec-
tion fraction (< 50%), history of congestive heart failure
and patient requiring surgery while hospitalized (Table
3).
Discussion
The poor long-term patency rates of SVG coupled with
reports citing the excellent long-term patency rates of and
improved survival associated with arterial grafts have
encouraged many to abandon the use of SVG in favour of
revascularization performed exclusively with arterial con-
duits[4-6,8,10]. The apparent increasing implementation
of TAG has been greatly facilitated by the development of
innovative surgical techniques, including Y- and T- graft
constructions, skeletonization of the internal mammary
arteries, as well as by the resurgence of sequential anasto-
moses [12-14]. While many case series have commented
on the safety of TAG, few studies have actually compared
outcomes following TAG with outcomes following the
traditional grafting strategy of LIMA+SVG [22]. Those that
have compared the two grafting strategies have reported
mixed short-term results (16 – 20), and data describing
long-term outcomes, where one would expect to see the
greatest impact of TAG, is lacking [16-19]. Taken together
TAG does not appear to have gained wide acceptance as
the standard of care which is best exemplified by the rela-
Risk adjusted freedom from readmission to hospital for car- diac reason between TAG group and LIMA+SVG group Figure 2
Risk adjusted freedom from readmission to hospital for car-
diac reason between TAG group and LIMA+SVG group.
Table 2: In-hospital and long-term outcomes following CABG with TAG and with LIMA+SVG
Outcome TAG (%) LIMA+SVG (%) p-value
In-hospital outcomes
Mortality 1.5 2.0 0.31
Stroke 1.6 1.8 0.67
Myocardial infarction 1.2 1.1 0.87
Long-term outcomes
All-cause mortality 8.4 18.6 < 0.0001
Readmission for any cardiac cause 28.8 37.9 < 0.0001
Composite outcome 33.5 46.6 < 0.0001
Risk adjusted freedom from mortality between TAG group  and LIMA+SVG group Figure 1
Risk adjusted freedom from mortality between TAG group 
and LIMA+SVG group.Journal of Cardiothoracic Surgery 2007, 2:44 http://www.cardiothoracicsurgery.org/content/2/1/44
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tive low proportion (~10%) of CABG patients receiving
exclusive arterial grafts[21,22].
In this study, we found that patients undergoing CABG
with TAG had fewer co-morbid illnesses and were more
likely to present with diminished coronary disease sever-
ity. In-hospital mortality did not differ significantly
between the two groups, but medium-term survival and
freedom from readmission to hospital was significantly
improved in patients undergoing TAG. However, when
differences between the two groups in terms of age, gen-
der, co-morbid illness, coronary disease severity and sur-
gical acuity were adjusted for using Cox proportional
hazard modeling techniques, TAG no longer emerged as
an independent predictor of freedom from long-term
adverse events following CABG. Unlike Lytle et al we were
unable to show that increased extent of arterial grafting
performed at primary coronary artery bypass grafting
decreased occurrence of coronary reoperation [23].
This retrospective study provides important comparisons
of medium-term outcomes between patients undergoing
CABG with TAG and patients undergoing CABG with the
more traditional LIMA+SVG. The absence in this study of
any impact of TAG on risk-adjusted long-term rates of all-
cause mortality and readmission to hospital for any car-
diac cause reaffirms the safety of this grafting strategy. To
date, retrospective studies comparing TAG and LIMA+SVG
have focused on in-hospital outcomes [16,20]. The only
studies that have compared TAG with LIMA+SVG on the
basis of both in-hospital and long-term outcomes were a
series of randomized clinical trials by Muneretto et al that
showed that while in-hospital morbidity and mortality
were similar between the two groups, TAG was associated
with increased freedom from the combined adverse out-
come of non-fatal MI, angina recurrence, graft occlusion,
need of PCI re-intervention and late death among patients
over the age of 50 as well as among elderly patients over
the age of 70 [17-19]. It should be noted, though, that
these trials were limited by reduced sample sizes (n = 200)
and limited duration of follow-up (mean follow-up 12 to
16 months). In addition, the manner in which TAG was
performed was restricted exclusively to composite graft
construction, which further limits the generalizability of
their results. More recently a large retrospective study
from Guru et al suggested that there is both a survival and
morbidity benefit to multiple arterial grafts as compared
to single arterial grafts [21]. The major strengths of their
study were the large size and length of follow-up. How-
ever, their results are also difficult to generalize as they
were derived from fewer than 6% of patients with 3-vessel
coronary disease and a relative small proportion of
selected patients receiving multiple arterial grafts (~12%
of CABG patients).
This study is not without its limitations, it can be argued
that the length of follow-up in this study is insufficient to
discern whether long-term rates of adverse events in fact
differ between patients undergoing CABG with TAG and
patients undergoing CABG with LIMA+SVG. The average
length of follow-up for this study for patients undergoing
TAG was 4.5 years, which is longer than the length of fol-
low-up from many previously published retrospective or
prospective analyses that have attempted to compare TAG
with conventional CABG. However, despite this limita-
tion we provide data on a large cohort (n = 1053) of exclu-
sively TAG patients compared to conventional LIMA+SVG
something very few have done before and demonstrate
the safety of TAG with the potential for long term benefit.
Secondly, because of the many different ways in which
Table 3: Fully-adjusted Cox-proportional hazards model with 
long-term composite outcome as the outcome (Death and/or 
readmission to hospital for cardiac reason)
Variable HR 95% CI p-value
Age 70–79 1.25 1.10–1.41 0.0004
Age 80+ 1.55 1.25–1.88 < 0.0001
COPD 1.39 1.24–1.57 < 0.0001
Female gender 1.14 1.04–1.26 0.006
Diabetes 1.28 1.17–1.40 < 0.0001
Pre-op renal failure 1.75 1.48–2.07 < 0.0001
Peripheral vascular disease 1.40 1.25–1.57 < 0.0001
Ejection fraction 30–49 1.22 1.09–1.36 0.006
Ejection fraction < 30 1.38 1.13–1.67 0.001
Congestive heart failure 1.33 1.17–1.52 < 0.0001
In-hospital urgent IHU (> 24 hours) 1.38 1.25–1.52 < 0.0001
Urgent (< 24 hours) 1.50 1.31–1.72 < 0.0001
pscore 0.86 0.67–1.10 0.222
Total arterial grafting (TAG) 0.92 0.76–1.11 0.397
Risk adjusted freedom from the composite outcome: death  and readmission to hospital for cardiac reason TAG group  and LIMA+SVG group Figure 3
Risk adjusted freedom from the composite outcome: death 
and readmission to hospital for cardiac reason TAG group 
and LIMA+SVG group.Journal of Cardiothoracic Surgery 2007, 2:44 http://www.cardiothoracicsurgery.org/content/2/1/44
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TAG can be accomplished surgically, a simple comparison
between all cases of CABG with TAG and cases of CABG
with LIMA+SVG underestimates, to some extent, the com-
plexity of the various TAG arrangements and the differing
impact that each arrangement may have on long-term
rates of adverse outcomes. For example, by including
cases in which composite Y- or T- grafts were used together
with cases in which a free arterial conduit was anastomo-
sed proximally to the aorta, we may be ignoring the
important effect that composite grafts may have on post-
operative outcomes independent of the whether or not
the CABG was performed with TAG. However, despite of
the underlying heterogeneity in surgical technique and
level of difficulty found among the different TAG arrange-
ments, we felt that the inclusion of the various arrange-
ments under a single entity more accurately represented a
typical practice in which TAG was performed on a regular
basis and better answered the broader question of
whether CABG performed with TAG was superior to
CABG performed with LIMA+SVG.
In conclusion, when compared to patients undergoing
CABG with LIMA+SVG, patients presenting for CABG
with TAG did so with fewer comorbidities and less coro-
nary disease severity. While in-hospital mortality rates
were similar between the two groups, patients undergoing
CABG with TAG had significantly lower medium-term
rates of all-cause mortality and readmission to hospital
for any cardiac cause. Following adjustment for differ-
ences between patients in terms of age, co-morbid illness
and extent of coronary disease, TAG did not emerge as a
significant predictor of freedom from medium-term
adverse events following CABG.
Abbreviations
CABG Coronary artery bypass surgery
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SVG Saphenous vein graft
TAG Total arterial grafting
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